18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

@article{Vandenberghe201018FflutemetamolAI,
  title={18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.},
  author={Rik Vandenberghe and Koen Van Laere and Adrian Ivanoiu and Eric Salmon and Christine Bastin and Eric Triau and Steen G. Hasselbalch and Ian Law and Allan Andersen and Alex Korner and Lennart Minthon and Ga{\"e}tan Garraux and Natalie Nelissen and Guy Bormans and Chris Buckley and Rikard Owenius and Lennart Thurfjell and Gill Farrar and David J. Brooks},
  journal={Annals of neurology},
  year={2010},
  volume={68 3},
  pages={
          319-29
        }
}

• Rik Vandenberghe, Koen Van Laere, +16 authors David J. Brooks
• Published in Annals of neurology 2010
• DOI:10.1002/ana.22068

OBJECTIVE The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology. METHODS Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15… CONTINUE READING

Save to Library

Create Alert

Cite

View on PubMed